VNDA:NASDAQVanda Pharmaceuticals Inc. Analysis

Vanda Pharmaceuticals trades at $6.24, hovering just above the computed support level of $5.61 and well below its 20‑day ($6.07), 50‑day ($6.30) and 200‑day ($6.51) simple moving averages, signaling a bearish price backdrop. The RSI sits at 51, indicating a neutral momentum, while the MACD histogram is positive and the MACD line sits above the signal line, suggesting a short‑term bullish tilt. Volume has been decreasing, the 30‑day volatility is high at ~39%, and beta is modest at 0.85, pointing to a stock that can swing sharply but is less correlated with the market. The company’s max drawdown of –40% underscores the downside risk that investors have already endured.
On the fundamentals side, VNDA posted $217.8 M in revenue with 3.4% growth and an impressive 94% gross margin, yet operating margins are deeply negative (‑97%) and the trailing EPS is –$4.06. Cash balances ($202 M) outweigh debt ($13 M), but the debt‑to‑equity ratio of 4.66 and negative free cash flow highlight balance‑sheet strain. Forward EPS is projected at $0.20, yielding a forward P/E of 31.2 versus an industry average of 28.9, and the stock trades at a modest 1.13× book value. Despite these challenges, H.C. Wainwright reiterated a **Strong Buy** with a $21 price target, implying a potential upside of over 120% and reflecting optimism around regulatory progress and the pipeline.